Immune checkpoints are signalling molecules that control the synapse between T cells and antigen presenting cells (APCs). Checkpoint inhibitor therapies target and inhibit the signals that ‘switch off’ T cells, leading to an upregulation of T cell activation and tumour cell killing. The mixed lymphocyte reaction (MLR) mimics the T cell and APC synapse by co-culturing immune cells from two individuals. MLR is used as a model to explore the effects of checkpoint inhibitor drugs in vitro; facilitating drug discovery processes and biological research applications.
What you will learn from this webinar: